Furthermore, FABP4 up-regulation induces IL-6/STAT3-mediated DNMT1 overexpression and the silencing of the p15INK4B tumor-suppressor gene in AML cells, thus confirming that FABP4 disruption may be a viable therapeutic strategy (65). Here, FABP4 is linked to neoplasm.